Protara Therapeutics (TARA) sustains 68% CR in ADVANCED-2 and activates $5.25 warrants

Rhea-AI Filing Summary

Protara Therapeutics, Inc. reported updated interim data from its ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with carcinoma in situ non-muscle invasive bladder cancer that is Bacillus Calmette-Guérin (BCG)-Unresponsive. The company confirmed the six-month complete response rate for the 25th BCG-Unresponsive patient, yielding an average six-month complete response rate of 68.0% in these 25 patients. This result is consistent with the previously announced six-month complete response rate of 68.2% and remains meaningfully above 41.9%. Based on this outcome, Protara determined that a condition in its April 2024 common stock purchase warrants has been satisfied, so those warrants are exercisable at $5.25 per share at any time on or prior to June 29, 2026.

Insights

Biotech & capital markets analyst

Phase 2 data meet a key warrant trigger, aligning clinical progress with potential equity dilution.

Protara reports a 68.0% six-month complete response rate in 25 BCG-Unresponsive non-muscle invasive bladder cancer patients in its Phase 2 ADVANCED-2 trial of TARA-002. This matches the earlier 68.2% figure and remains well above 41.9%, which is highlighted as a meaningful benchmark.

Clinically, sustaining this response rate as the cohort matures supports continued development of TARA-002 in this difficult-to-treat setting. Financially, the data satisfy a condition embedded in the April 2024 common stock warrants, making them exercisable at $5.25 per share until June 29, 2026.

This structure links trial performance to potential share issuance if holders choose to exercise. Any future impact on the share count or cash position will depend on actual warrant exercises, which are not specified here and would be reflected in subsequent disclosures.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Understanding 8-K Material Events →

false 0001359931 0001359931 2026-03-30 2026-03-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 30, 2026

Protara Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-36694		20-4580525
(State or other jurisdiction of incorporation)		(Commission File No.)		(IRS Employer Identification No.)

345 Park Avenue South Third Floor New York, NY		10010
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (646) 844-0337 

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		TARA		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

Item 7.01 Regulation FD Disclosure.

On March 30, 2026, Protara Therapeutics, Inc. (the “Company” or “Protara”) announced that the Company has received confirmation on the six-month complete response (“CR”) rate of the 25^th Bacillus Calmette-Guérin (“BCG”)-Unresponsive patient in its ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with carcinoma in situ or CIS (± Ta/T1) non-muscle invasive bladder cancer (“NMIBC”). The average six-month CR rate in the 25 BCG-Unresponsive patients is 68.0%, which is consistent with the 68.2% CR rate at six months that was announced by the Company on February 24, 2026, and is meaningfully above 41.9%.

As a result, the Company has determined that it has satisfied the condition set forth in its common stock purchase warrants issued in April 2024 (the “April 2024 Common Warrants”) for fixing the termination date for exercise of the April 2024 Common Warrants. Specifically, the April 2024 Common Warrants are exercisable at an exercise price of $5.25 per share and may be exercised at any time on or prior to June 29, 2026.

The information contained in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 30, 2026

	Protara Therapeutics, Inc.
	By:	/s/ Patrick Fabbio
		Patrick Fabbio
		Chief Financial Officer

2

FAQ

What trial results did Protara Therapeutics (TARA) report for TARA-002?

Protara reported a six-month complete response rate of 68.0% in 25 BCG-Unresponsive non-muscle invasive bladder cancer patients in its Phase 2 ADVANCED-2 trial. This rate matches prior interim data and is described as meaningfully above 41.9%, reinforcing the regimen’s observed activity.

How do the new Protara (TARA) ADVANCED-2 results compare to earlier data?

The new six-month complete response rate of 68.0% across 25 BCG-Unresponsive patients is consistent with the previously announced 68.2% rate. This stability as more patients reach six-month follow-up suggests the observed efficacy signal for TARA-002 is being maintained in the trial cohort.

What are the key details of Protara’s April 2024 common stock warrants?

Protara’s April 2024 common stock warrants are exercisable at an exercise price of $5.25 per share. Following satisfaction of a specified clinical condition, the warrants may now be exercised at any time on or prior to June 29, 2026, giving holders a defined exercise window.

What condition related to Protara’s April 2024 warrants has been satisfied?

The company determined that a clinical condition tied to its ADVANCED-2 Phase 2 trial results has been satisfied. This condition related to confirming the six-month complete response rate for BCG-Unresponsive patients, enabling the company to fix the termination date for exercise of the April 2024 common stock warrants.

Does Protara (TARA) receive cash immediately from the April 2024 warrant terms?

The disclosed information states that the April 2024 common stock warrants are exercisable at $5.25 per share until June 29, 2026. Any cash inflow to Protara would depend on warrant holders choosing to exercise, which is not addressed in this specific disclosure.

What type of bladder cancer is targeted in Protara’s ADVANCED-2 trial?

The ADVANCED-2 trial evaluates TARA-002 in patients with carcinoma in situ, or CIS (± Ta/T1), non-muscle invasive bladder cancer that is Bacillus Calmette-Guérin (BCG)-Unresponsive. This population has limited treatment options after BCG failure, making durable complete responses clinically important.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB